Biogen Idec, Inc. (Massachusetts) Announces Collaboration With Leading Research Institutions to Sequence Genomes of Patients With ALS
WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that it has entered into a research collaboration with premier academic and research institutions to sequence the genomes of up to 1,000 patients with amyotrophic lateral sclerosis (ALS) in an effort to gain a deeper understanding about the fundamental genetic causes of ALS.